基于症状综合管理模式的卵巢癌患者化疗不良反应症状群管理工具包方案的制订及应用  

Development and application of a toolkit program for managing symptom clusters of adverse reactions to chemotherapy for ovarian cancer based on a comprehensive symptom management model

作　　者：柴佩珊 韩文萍 李红梅[1] 郝丽敏 韩慧琴 孙桥 李敏 曹艳行 Chai Peishan;Han Wenping;Li Hongmei;Hao Limin;Han Huiqin;Sun Qiao;Li Min;Cao Yanxing(Fenyang College,Shanxi Medical University,Fenyang 032200,China;Otolaryngology of Fenyang Hospital of Shanxi Province,Fenyang 032200,China)

机构地区：[1]山西医科大学汾阳学院,汾阳032200 [2]山西省汾阳医院妇科,汾阳032200

出　　处：《中国实用护理杂志》2024年第35期2721-2729,共9页Chinese Journal of Practical Nursing

基　　金：吕梁市科技计划项目(2020ZDSYS15)。

摘　　要：目的探讨基于症状综合管理模式的卵巢癌患者化疗不良反应症状群管理工具包方案对卵巢癌患者症状状态、自我护理能力及生命质量的影响,为临床指导卵巢癌患者进行化疗不良反应症状管理提供指导。方法采用非同期前后对照研究,便利抽样法选取山西省汾阳医院妇科2022年8月至2023年1月收治的45例卵巢癌化疗患者作为对照组,2023年2—7月的45例卵巢癌化疗患者作为试验组。对照组采用常规护理,试验组在常规护理基础上采用症状群管理工具包方案。于干预前及第1、2、3次化疗周期结束后采用癌症患者生命质量测定量表、自我护理能力量表对2组患者进行测评,于第1、2、3次化疗周期结束后采用不良反应事件评价标准5.0对2组进行测评,比较2组患者症状状态、自我护理能力及生命质量。结果最终纳入对照组43例,试验组41例,对照组年龄为(59.37±8.61)岁,试验组为(57.10±9.97)岁。干预后,第1、2、3次化疗周期结束后不良反应评级分别为:恶心评级试验组为1(1,2)、1(1,2)、2(1,2)级,对照组为2(1,2)、2(1,2)、2(1,2)级;呕吐评级试验组为1(1,2)、1(1,2)、1(1,2)级,对照组为2(1,2)、2(1,2)、2(1,2)级;外周感觉神经障碍评级试验组为1(1,1)、1(1,1)、1(1,2)级,对照组为1(1,1)、1(1,2)、2(1,2)级;外周运动神经障碍评级试验组为1(1,1)、1(1,1)、1(1,1)级,对照组为1(1,1)、1(1,2)、2(1,2)级;认知障碍评级试验组为1(1,1)、1(1,1)、1(1,1)级,对照组为1(1,1)、1(1,2)、1(1,2)级,差异均有统计学意义(Waldχ2值为4.41~6.54,均P<0.05)。卵巢癌患者第1、2、3次化疗周期结束后对照组自我护理能力得分分别为(106.30±13.03)、(109.53±13.85)、(111.95±13.49)分,试验组分别为(113.68±11.33)、(118.95±11.39)、(123.66±11.67)分,试验组自我护理能力水平高于对照组,差异有统计学意义(F=8.61,P<0.05);而生命质量第1、2、3次化疗周期结束后对照组得分分别为(65.35�Objective To explore the effects of the toolkit program for managing symptom clusters of adverse reactions to chemotherapy for ovarian cancer based on the comprehensive symptom management model on the symptom status,self-care ability and quality of life of ovarian cancer patients,and to provide guidance for clinical guidance on symptom management of adverse reactions to chemotherapy for ovarian cancer patients.Methods A non-simultaneous before-and-after control was used to facilitate the selection of 45 ovarian cancer chemotherapy patients from the Department of Gynecology,Fenyang Hospital,Shanxi Province,from August 2022 to January 2023 as the control group,and 45 ovarian cancer chemotherapy patients from February to July 2023 as the experimeatal group.Routine care was used in the control group,and the experimental group used the Symptom Cluster Management Toolkit program based on the control group.Before intervention and after the end of the first,second,and third chemotherapy cycles,two groups of patients were evaluated using the Functional Assessment of Cancer Therapy-Generic scale and Exercise of Self-Care Agency Scale;after the end of the first,second,and third chemotherapy cycles,Adverse Reaction Events Evaluation Criteria 5.0 was used to evaluate the two groups.The symptom status,self-care ability,and quality of life between two groups of patients were compared.Results Finally 43 cases in control group and 41 cases in experimental group were included,age of control group was(59.37±8.61)years old and experimental group was(57.10±9.97)years old.After intervention,at the end of the first,second,and third chemotherapy cycles were assessed for side effects,respectively:the nausea rating of the experimental group were 1(1,2),1(1,2),2(1,2),and the control group were 2(1,2),2(1,2),2(1,2);the vomiting rating of the experimental group were 1(1,2),1(1,2),1(1,2),and the control group were 2(1,2),2(1,2),2(1,2);peripheral sensory nerve disorder rating of the experimental group were 1(1,1),1(1,1),1(1,2),and the contro

关 键 词：卵巢肿瘤 化疗 症状管理 症状群 工具包 

分 类 号：R473.73[医药卫生—护理学]